Also, miR-22 impairs the MLL-AF9-induced leukemogenesis through repressing CREB and Myc pathways and relieves the monocyte/macrophage differentiation and the growth of AML by targeting MECOM (81, 82). This evidence concerns the gene MECOM and acute myeloid leukemia.